TOXICOLOGICAL PROFILE FOR PERCHLORATES

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2008
DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.
UPDATE STATEMENT

A Toxicological Profile for Perchlorates, Draft for Public Comment was released in July 2005. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. ATSDR considers updating Toxicological profile as new research data becomes available that may significantly impact the Minimal Risk Levels (MRLs) or other conclusions. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-32
Atlanta, Georgia 30333
This page is intentionally blank.
FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance’s toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance’s relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance’s health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Howard Frumkin M.D., Dr.P.H.  
Director  
National Center for Environmental Health/Agency for Toxic Substances and Disease Registry

Julie Louise Gerberding, M.D., M.P.H.  
Administrator  
Agency for Toxic Substances and Disease Registry

*Legislative Background*

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99 499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on December 7, 2005 (70 FR 72840). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486); April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999 (64 FR 56792); October 25, 2001 (66 FR 54014) and November 7, 2003 (68 FR 63098). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.
QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children

Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects

ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or Fax: (770) 488-4178
1-888-232-6348 (TTY)
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include Reproductive and Developmental Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Sharon Wilbur, M.A.
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Gary Diamond, Ph.D.
Fernando Llados, Ph.D.
Marc Odin, M.S., D.A.B.T.
Mario Citra, Ph.D.
Daniel Plewak, B.S.
Jay Tunkel, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.

2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

This page is intentionally blank.
PEER REVIEW

Peer reviewers were selected to review the ATSDR Toxicological Profile for Perchlorates.

The post-public comment draft was reviewed on April 18, 2007 by:

1. Dr. Jeffrey Fisher, Department Head and Professor, Department of Environmental Health Science, the University of Georgia, Athens, Georgia;
2. Dr. Stephen LaFranchi, Professor, Department of Pediatrics, Head, Pediatric Endocrinology, Associate Chair for Education, Oregon Health Sciences University (CDRCP), Portland, Oregon;
3. Dr. Kannan Krishnan, Professor of Occupational and Environmental Health, University of Montreal, Montreal, Quebec, Canada; and
4. Dr. R. Thomas Zoeller, Professor, Department of Biology, University of Massachusetts at Amherst, Morrill Science Center, Amherst, Massachusetts.

The pre-public comment draft was reviewed on June 26, 2002 by:

1. Dr. Kannan Krishnan, Professor of Occupational and Environmental Health, University of Montreal, Montreal, Quebec, Canada;
2. Dr. R. Thomas Zoeller, Professor, Department of Biology, University of Massachusetts at Amherst, Morrill Science Center, Amherst, Massachusetts; and
3. Dr. Gary Williams, Professor of Pathology, Department of Pathology, New York Medical College, Valhalla, New York.

These experts collectively have knowledge of perchlorates' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR. Nevertheless, the expert peer reviewers on April 18, 2007 concluded that the minimal risk level (MRL) should still be based on the Reference Dose (RfD) as recommended by the NAS Panel Report (2005) given the research data available at the time of the 2007 peer review.
## CONTENTS

DISCLAIMER ........................................................................................................... ii
UPDATE STATEMENT ............................................................................................ iii
FOREWORD ............................................................................................................. v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS ........................................ vii
CONTRIBUTORS .................................................................................................... ix
PEER REVIEW .......................................................................................................... xi
CONTENTS .............................................................................................................. xiii
LIST OF FIGURES ................................................................................................. xvii
LIST OF TABLES ..................................................................................................... xix

1. PUBLIC HEALTH STATEMENT ......................................................................... 1
   1.1 WHAT ARE PERCHLORATES? ........................................................................ 1
   1.2 WHAT HAPPENS TO PERCHLORATES WHEN THEY ENTER THE
       ENVIRONMENT? ............................................................................................. 3
   1.3 HOW MIGHT I BE EXPOSED TO PERCHLORATES? ...................................... 5
   1.4 HOW CAN PERCHLORATES ENTER AND LEAVE MY BODY? ....................... 6
   1.5 HOW CAN PERCHLORATES AFFECT MY HEALTH? ....................................... 7
   1.6 HOW CAN PERCHLORATES AFFECT CHILDREN? .......................................... 9
   1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO PERCHLORATES?.... 10
   1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED
       TO PERCHLORATES? ................................................................................. 11
   1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
       PROTECT HUMAN HEALTH? ...................................................................... 11
   1.10 WHERE CAN I GET MORE INFORMATION? .................................................. 13

2. RELEVANCE TO PUBLIC HEALTH ....................................................................... 15
   2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO PERCHLORATES IN
       THE UNITED STATES .................................................................................... 15
   2.2 SUMMARY OF HEALTH EFFECTS .................................................................. 17
   2.3 MINIMAL RISK LEVELS (MRLs) ..................................................................... 22

3. HEALTH EFFECTS .............................................................................................. 27
   3.1 INTRODUCTION ............................................................................................ 27
   3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE ................. 27
      3.2.1 Inhalation Exposure .................................................................................. 28
         3.2.1.1 Death ............................................................................................... 28
         3.2.1.2 Systemic Effects .............................................................................. 28
         3.2.1.3 Immunological and Lymphoreticular Effects ................................. 33
         3.2.1.4 Neurological Effects ........................................................................ 33
         3.2.1.5 Reproductive Effects ...................................................................... 33
         3.2.1.6 Developmental Effects .................................................................... 33
         3.2.1.7 Cancer .............................................................................................. 33
      3.2.2 Oral Exposure .......................................................................................... 33
         3.2.2.1 Death ............................................................................................... 33
         3.2.2.2 Systemic Effects .............................................................................. 33
         3.2.2.3 Immunological and Lymphoreticular Effects ................................. 65
         3.2.2.4 Neurological Effects ........................................................................ 67
         3.2.2.5 Reproductive Effects ...................................................................... 67
         3.2.2.6 Developmental Effects .................................................................... 69
3.2.2.7 Cancer ........................................................................................................ 79
3.2.3 Dermal Exposure ........................................................................................................... 80
3.2.3.1 Death ................................................................................................................... 80
3.2.3.2 Systemic Effects ................................................................................................. 80
3.2.3.3 Immunological and Lymphoreticular Effects ....................................................... 80
3.2.3.4 Neurological Effects .......................................................................................... 80
3.2.3.5 Reproductive Effects ......................................................................................... 80
3.2.3.6 Developmental Effects ....................................................................................... 80
3.2.3.7 Cancer ................................................................................................................ 80
3.3 GENOTOXICITY ........................................................................................................... 80
3.4 TOXICOKINETICS ....................................................................................................... 81
3.4.1 Absorption ............................................................................................................... 81
3.4.1.1 Inhalation Exposure ............................................................................................ 81
3.4.1.2 Oral Exposure .................................................................................................... 82
3.4.1.3 Dermal Exposure ............................................................................................... 82
3.4.2 Distribution .............................................................................................................. 83
3.4.2.1 Inhalation Exposure ........................................................................................... 83
3.4.2.2 Oral Exposure ................................................................................................... 83
3.4.2.3 Dermal Exposure ............................................................................................... 84
3.4.2.4 Other Routes of Exposure .................................................................................. 84
3.4.3 Metabolism .............................................................................................................. 85
3.4.4 Elimination and Excretion ....................................................................................... 85
3.4.4.1 Inhalation Exposure ........................................................................................... 85
3.4.4.2 Oral Exposure ................................................................................................... 86
3.4.4.3 Dermal Exposure ............................................................................................... 86
3.4.4.4 Other Routes of Exposure .................................................................................. 87
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .... 87
3.5 MECHANISMS OF ACTION ......................................................................................... 108
3.5.1 Pharmacokinetic Mechanisms ............................................................................... 108
3.5.2 Mechanisms of Toxicity ........................................................................................ 110
3.5.3 Animal-to-Human Extrapolations ........................................................................ 120
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS ...................... 123
3.7 CHILDREN’S SUSCEPTIBILITY .................................................................................. 126
3.8 BIOMARKERS OF EXPOSURE AND EFFECT .............................................................. 129
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Perchlorates ..................... 130
3.8.2 Biomarkers Used to Characterize Effects Caused by Perchlorates ..................... 132
3.9 INTERACTIONS WITH OTHER CHEMICALS ............................................................... 132
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ........................................ 134
3.11 METHODS FOR REDUCING TOXIC EFFECTS .......................................................... 135
3.11.1 Reducing Peak Absorption Following Exposure ................................................ 136
3.11.2 Reducing Body Burden ....................................................................................... 136
3.11.3 Interfering with the Mechanism of Action for Toxic Effects ............................... 136
3.12 ADEQUACY OF THE DATABASE ............................................................................. 136
3.12.1 Existing Information on Health Effects of Perchlorates ..................................... 137
3.12.2 Identification of Data Needs ............................................................................... 137
3.12.3 Ongoing Studies .................................................................................................. 146

4. CHEMICAL AND PHYSICAL INFORMATION ................................................................. 149
4.1 CHEMICAL IDENTITY ................................................................................................ 149
4.2 PHYSICAL AND CHEMICAL PROPERTIES ................................................................ 149
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL ................................................................. 153
  5.1 PRODUCTION .................................................................................................................. 153
  5.2 IMPORT/EXPORT ........................................................................................................... 156
  5.3 USE ............................................................................................................................... 157
  5.4 DISPOSAL ....................................................................................................................... 161

6. POTENTIAL FOR HUMAN EXPOSURE .................................................................................. 165
  6.1 OVERVIEW .................................................................................................................... 165
  6.2 RELEASES TO THE ENVIRONMENT .............................................................................. 169
      6.2.1 Air .......................................................................................................................... 169
      6.2.2 Water ..................................................................................................................... 171
      6.2.3 Soil ......................................................................................................................... 172
  6.3 ENVIRONMENTAL FATE .................................................................................................. 173
      6.3.1 Transport and Partitioning ..................................................................................... 174
      6.3.2 Transformation and Degradation ............................................................................ 176
          6.3.2.1 Air ................................................................................................................... 176
          6.3.2.2 Water .............................................................................................................. 177
          6.3.2.3 Sediment and Soil .......................................................................................... 179
  6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT ................................. 179
      6.4.1 Air .......................................................................................................................... 180
      6.4.2 Water ..................................................................................................................... 180
      6.4.3 Sediment and Soil ................................................................................................. 184
      6.4.4 Other Media .......................................................................................................... 185
  6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE ...................................... 191
  6.6 EXPOSURES OF CHILDREN .......................................................................................... 194
  6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES ........................................... 196
  6.8 ADEQUACY OF THE DATABASE .................................................................................... 197
      6.8.1 Identification of Data Needs ................................................................................... 197
      6.8.2 Ongoing Studies .................................................................................................... 202

7. ANALYTICAL METHODS ..................................................................................................... 205
  7.1 BIOLOGICAL MATERIALS ............................................................................................. 206
  7.2 ENVIRONMENTAL SAMPLES ........................................................................................ 207
  7.3 ADEQUACY OF THE DATABASE ..................................................................................... 208
      7.3.1 Identification of Data Needs ................................................................................... 208
      7.3.2 Ongoing Studies .................................................................................................... 209

8. REGULATIONS AND ADVISORIES ...................................................................................... 211

9. REFERENCES ......................................................................................................................... 217

10. GLOSSARY ........................................................................................................................... 251

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS ...................................................... A-1
B. USER’S GUIDE .................................................................................................................... B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS .............................................................. C-1
D. INDEX ................................................................................................................................. D-1
This page is intentionally blank.
LIST OF FIGURES

3-1. Levels of Significant Exposure to Perchlorates – Inhalation................................................................. 31

3-2. Levels of Significant Exposure to Perchlorates – Oral................................................................................................. 49

3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance........................................................................................................ 89

3-4. Structure of PBPK Model of Perchlorate in Typical Adult Humans and Male Rats............................... 93

3-5. Structure of PBPK Models of Perchlorate in the Pregnant and Lactating Woman ......................... 94

3-6. Pathways Uptake and Metabolism of Iodide in the Thyroid Gland................................................................. 111

3-7. Hypothalamic-pituitary-thyroid (HPT) Feedback Pathways for Regulation of Thyroid Hormone Production and Secretion ........................................................................................................ 113

3-8. Comparison of Dose-Response Relationships for the Inhibitory Effect of Perchlorate on 24-hour Thyroid Iodide Uptake in Humans and Rats .................................................................................. 122

3-9. Changes in Serum Thyroid Hormone Levels in Rats Exposed to Perchlorate in Drinking Water for 14 Days.......................................................................................................................... 124

3-10. Existing Information on Health Effects of Perchlorate ................................................................................. 138

6-1. Frequency of NPL Sites with Perchlorate Contamination..................................................................................... 166
This page is intentionally blank.
LIST OF TABLES

3-1. Levels of Significant Exposure to Perchlorates – Inhalation.......................... 30
3-2. Levels of Significant Exposure to Perchlorates – Oral................................. 34
3-3. Perchlorate and Radioiodide Parameter Values for the Adult Male Rat and Human PBPK Models................................................................. 91
3-4. Perchlorate Chemical-specific Parameters for Human Gestation and Lactation Models.............................. 96
3-5. Radioiodide Chemical-specific Parameters for Human Gestation and Lactation Models.................. 98
3-6. Perchlorate Chemical-specific Parameters for Rat Gestation and Lactation Models .................. 100
3-7. Iodide Chemical-specific Parameters for Rat Gestation and Lactation Models .................. 102
3-8. Model-predicted Serum ClO₄⁻ Area Under the Curve (AUC) Across Lifestages........... 106
3-9. Model-predicted Inhibition of Thyroid Iodide Uptake (Percent Inhibition) Across Lifestages .... 107
3-10. Typical Reference Ranges for Serum Thyroid Hormones and TSH in Humans .............. 116
4-1. Chemical Identity of Perchlorates ............................................................... 150
4-2. Physical and Chemical Properties of Perchlorates ....................................... 151
5-1. U.S. Manufacturers of Perchlorates............................................................. 154
5-2. Import and Export Data for Products that may Contain Perchlorate ................. 158
6-1. Measurements of Perchlorate in Samples of 27 Types of Food and Beverages Collected From Various Locations in the United States................................................. 187
6-4. Ongoing Studies on the Potential for Human Exposure to Perchlorates (Including Studies on Fate and Occurrence) ................................................................. 203
8-1. Regulations and Guidelines Applicable to Perchlorates.................................. 213